BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18224667)

  • 1. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
    Ma W; Kantarjian H; O'Brien S; Jilani I; Zhang X; Estrov Z; Ferrajoli A; Keating M; Giles F; Albitar M
    Cancer; 2008 Mar; 112(6):1306-12. PubMed ID: 18224667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.
    Delgado J; Pratt G; Phillips N; Briones J; Fegan C; Nomdedeu J; Pepper C; Aventin A; Ayats R; Brunet S; Martino R; Valcarcel D; Milligan D; Sierra J
    Br J Haematol; 2009 Jun; 145(6):801-5. PubMed ID: 19388937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
    van't Veer MB; Brooijmans AM; Langerak AW; Verhaaf B; Goudswaard CS; Graveland WJ; van Lom K; Valk PJ
    Haematologica; 2006 Jan; 91(1):56-63. PubMed ID: 16434371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
    Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
    Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
    Lai R; O'Brien S; Maushouri T; Rogers A; Kantarjian H; Keating M; Albitar M
    Cancer; 2002 Sep; 95(5):1071-5. PubMed ID: 12209693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
    Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
    Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
    Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.
    Smolej L; Andrys C; Peková S; Schwarz J; Belada D; Zák P
    Haematologica; 2006 Oct; 91(10):1432-3. PubMed ID: 17018398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IgVH mutation status in patients with chronic lymphocytic leukemia].
    Zhang YP; Chen LJ; Zheng WJ; Wu YJ; Qiu HX; Qian SX; Xu W; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):164-7. PubMed ID: 18788614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity.
    Mansouri M; Sevov M; Fahlgren E; Tobin G; Jondal M; Osorio L; Roos G; Olivecrona G; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):301-6. PubMed ID: 19709746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
    Chen YH; Peterson LC; Dittmann D; Evens A; Rosen S; Khoong A; Shankey TV; Forman M; Gupta R; Goolsby CL
    Am J Clin Pathol; 2007 Feb; 127(2):182-91. PubMed ID: 17210531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.
    Pratt G; Harding S; Holder R; Fegan C; Pepper C; Oscier D; Gardiner A; Bradwell AR; Mead G
    Br J Haematol; 2009 Jan; 144(2):217-22. PubMed ID: 19016722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
    Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
    Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.
    Martinelli S; Maffei R; Castelli I; Santachiara R; Zucchini P; Fontana M; Bonacorsi G; Leonardi G; Marasca R; Torelli G
    Leuk Res; 2008 Apr; 32(4):593-7. PubMed ID: 17928052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
    Kharfan-Dabaja MA; Chavez JC; Khorfan KA; Pinilla-Ibarz J
    Cancer; 2008 Sep; 113(5):897-906. PubMed ID: 18618518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.